Liver Cancer Study: Comparing Two Chemotherapy Drugs via Artery Infusion
Part of Cancer, Digestive system clinical trials.
This study compares two chemotherapy drugs (raltitrexed and 5-fluorouracil) given directly into the liver's main artery to treat liver cancer. It aims to see which drug works better and is safer for people with hepatocellular carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- You must not have fluid in your belly, chest, or around your heart that needs regular draining.
- You must not have HIV or a history of organ or stem cell transplant.
- You must not have serious heart problems or recent blood clots.
- You must not have had stomach/intestinal bleeding in the last 6 months or have high-risk esophageal varices.
- You must not have another active cancer that was treated less than 5 years ago (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests whether giving chemotherapy directly into the liver blood supply before a liver transplant can help people with liver cancer that is beyond standard transplant criteria. It may help lower cancer risk around the time of transplant while keeping people healthy enough to receive the transplant.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests giving chemotherapy directly into the liver artery (HAIC) mixed with a special oil called lipiodol. It may help people with advanced liver cancer that cannot be treated with standard methods or who cannot tolerate them.
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.